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Abstract 
Background: The Democratic Republic of the Congo (DRC) changed its national policy for the treatment of severe 
malaria in both children and adults in 2012 from intravenous quinine to injectable artesunate. The country is now 
planning to deploy nationwide injectable artesunate as the preferred treatment for the management of severe 
malaria. To support this process, the feasibility and acceptability of the use of injectable artesunate in the context of 
the DRC was assessed, from the perspective of both health care providers and patients/caretakers.
Methods: Questionnaires and observations were used to collect information from health care providers and 
patients/caretakers in eight health facilities in the Province of Kinshasa and in the Province of Bas-Congo.
Results: A total of 31 health care providers and 134 patients/care takers were interviewed. Seventy five percent 
(75 %) of health care providers found it less difficult to prepare injectable artesunate compared to quinine. None 
of them encountered problems during preparation and administration of injectable artesunate. The large major-
ity of care providers (93 %) and patients/caretakers (93 %) answered that injectable artesunate took less time than 
quinine to cure the symptoms of the patients. 26 (84 %) health care providers reported that the personnel workload 
had diminished with the use of injectable artesunate. 7 (22.6 %) health workers reported adverse drug reactions, of 
which a decrease in the haemoglobin rate was the most common (71.4 %). All care providers and the vast majority of 
patients/caretakers (96 %, N = 128) were either satisfied or very satisfied with injectable artesunate.
Conclusions: These findings show that the use of injectable artesunate for the treatment of severe malaria is feasible 
and acceptable in the context of DRC, with appropriate training of care providers. Both care providers and patients/
caretakers perceived injectable artesunate to be effective and safe, thus promoting acceptability.
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Background
In the Democratic Republic of the Congo (DRC), malaria 
is one of the leading causes of death in children under 
5  years of age, with an estimated 9,000,000 cases and 
22,000 deaths reported in 2012 [1]. As a result, the DRC 
is the second country in the world in terms of burden 
of malaria [2, 3]. For severe malaria, the case fatality is 
reaching 10 % [4]. Severe malaria is obviously a medical 
emergency, and reducing its burden is currently the high-
est priority of malaria control, as evidenced by the Roll 
Back malaria (RBM) target of near-zero deaths by 2015 
[5].
For the management of severe malaria cases, com-
parative clinical trials between quinine and injectable 
artesunate have demonstrated that the treatment with 
artesunate was associated with a substantial reduc-
tion of case fatality in both children and adults [6–8]. 
In addition, intravenous artesunate offers a number of 
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programmatic advantages over quinine in terms of not 
requiring rate-controlled infusion or cardiac monitoring 
[9]. These results led to a change in the WHO guidelines 
for the treatment of severe malaria in 2011, recom-
mending intravenous artesunate as the preferred treat-
ment for severe malaria in children and adults [10]. As a 
result of this change, an additional 195,000 deaths could 
be averted every year in Africa [11]. Following the new 
WHO guidelines, the National Malaria Control Pro-
gramme (NMCP) of the DRC changed the national policy 
for the treatment of severe malaria in both children and 
adults from intravenous quinine to injectable artesunate 
in 2012 [12]. However, this policy change requires a num-
ber of clinical and operational adaptations, as quinine 
has been the treatment of choice for many decades. The 
national strategic plan set up an implementation period 
of 3 years to scale up injectable artesunate.
The handling of injectable artesunate is reported to be 
easier compared to quinine, however a number of opera-
tional issues such as dosing and preparation of the drug 
may hinder its use.
One important element for a successful transition, 
besides logistical aspects, is ensuring that there is a high 
acceptability of the new treatment by the health care pro-
viders, as well as by the patients. Finally, there is also a 
need to determine the perceived effectiveness and safety 
of the new treatment. These factors are a prerequisite for 
achieving a successful rollout and therefore high public 
health impact. This study investigates the feasibility and 
acceptability of the use of injectable artesunate in the 
context of the DRC, to identify arising issues and propose 
solutions before the start of the national rollout.
Although a number of studies have investigated the effi-
cacy of injectable artesunate for the treatment of severe 
malaria as well as some issues related to its use [13–15], 
none has focused so far on the feasibility of the imple-
mentation of the new IV/IM anti-malarial drug from the 
perspective of care providers, as well as its acceptability 
from the perspective of patients/caretakers.
Methods
Study sites
This study was conducted as part of the MATIAS study 
(Treatment of severe malaria—an operational compara-
tive study for the treatment of severe malaria between 
quinine and artesunate in Hospitals and Health Centres 
of Kinshasa and Bas Congo province). The MATIAS 
study was a non-controlled operational comparative 
study conducted in children and adults admitted with 
severe malaria to hospital and health centres [16].
The study was implemented in eight health facili-
ties (three hospitals and five health centres) in Greater 
Kinshasa, the capital of the DRC (Referral Hospital Roi 
Baudoin, Health Centre Bita, Health Centre Menkao) and 
in the Province of Bas-Congo (Referral Hospital Saint 
Luc Kisantu, Health Centre Ngeba, Referral hospital of 
Kimpese, Health Centre Ceco, Health Centre La Famille). 
Figure  1 shows the location of the study sites. Selected 
health facilities were representative of typical health 
facilities in the country including a large public health 
hospital; a medium-sized, non-profit, missionary hospi-
tal; a medium-sized, government hospital (Centre Hospi-
talier Roi Baudouin) and rural health centres.
Kinshasa sites serve urban and semi-rural populations, 
whereas the Bas-Congo sites serve a largely rural popula-
tion. All sites are hyper to holoendemic for malaria and 
transmission is perennial with seasonal variation [17, 18]. 
At the time the study started, injectable artesunate had 
not been deployed to public health facilities and was not 
available in the private sector.
The MATIAS study was conducted in two consecu-
tive phases. In the first phase, in the eight selected study 
sites, a target number of 350 patients were recruited 
over 3 months, from October 2012 to January 2013, with 
intravenous quinine as the treatment drug. In the second 
phase, following the introduction of injectable artesunate, 
the same target number of patients was recruited over 
the 3  months period, from April to July 2013. A three-
month interval was kept between the two phases in order 
to train the healthcare providers from the study sites in 
the preparation and administration of the new drug.
With regard to the use of injectable artesunate in hospi-
tals, clinicians were responsible for prescribing the drug, 
specifying the dose needed and the schedule of dosing 
and evaluating patients’ progress while nurses prepared 
and administered the drug. In health centres, nurses were 
responsible for all aspects of drug use.
The MATIAS study included four key components: 
(1) clinical assessment of patients, (2) a time and motion 
study, (3) financial costs, (4) feasibility and acceptability 
assessments through providers and patients/caretak-
ers questionnaires. The results of the first three compo-
nents are reported elsewhere [16], while the results of the 
fourth component are reported here.
All interviews for the feasibility and acceptability 
assessment were conducted during the second phase 
(artesunate phase) between April and July 2013, since the 
aim was chiefly to compare assessments of quinine versus 
artesunate.
Participants belonged to two groups with separate 
questionnaires: (1) Health care providers who pre-
scribed or administered injectable artesunate dur-
ing the MATIAS study and whose verbal consent was 
obtained. A purposive sample of four health care pro-
viders per health facility was interviewed, which repre-
sents the mean number of personnel trained in the use 
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of injectable artesunate per health facility. (2) patients/
caretakers of patients who were treated with injectable 
artesunate in each study site. A convenience sample of 
one-third of all patients/caretakers of patients attending 
follow up visits was interviewed. Patients/caretakers of 
patients were eligible for interview if they had personal 
past experience with quinine treatment or have taken 
care of another member of the family in the past treated 
with quinine and they must give verbal consent. Patients 
or caretakers of patients were randomly selected.
Training and implementation of injectable artesunate
In preparation for the first part of the study (quinine 
treatment), a three-day training on study procedures 
was given to all investigators and staff involved in the 
patient’s clinical management in each hospital and health 
centre. The training included an update of knowledge on 
malaria diagnosis and management. Before starting the 
second phase, a two-day training on the preparation and 
administration of injectable artesunate was given to all 
staff involved in clinical management in the study sites. 
These sessions used a new training tool kit developed and 
provided by the Medicines for Malaria Venture (MMV) 
product development partnership. This kit consisted of a 
very detailed user guide; an explicit and straightforward 
job aid (Fig.  2), and a practical training video. Prior to 
patient recruitment, health care providers were allowed 
some time to become familiar with the handling of the 
new drug under supervision.
Injectable artesunate (Guilin Pharmaceutical Co, Ltd, 
Shanghai, China) was packed in boxes each contain-
ing one vial of 60 mg of artesunate powder for injection, 
one ampoule of sodium bicarbonate and one ampoule of 
sodium chloride. The following steps were required prior 
to drug injection: (1) calculation of the number of vials 
required based on patient weight, (2) reconstitution of 
artesunate solution with sodium bicarbonate solution, (3) 
dilution of the solution with sodium chloride.
Artesunate was given intravenously at a dose of 2.4 mg/
kg bodyweight at 0, 12 and 24  h, and then once a day 
until the patient was able to take oral treatment. In line 
with the WHO recommendations [9], parenteral treat-
ment was given for a minimum of 24 h, irrespective of the 
patient’s ability to tolerate oral medication. After comple-
tion of the injectable treatment, the patient was given a 
full course of the recommended oral artemisinin-based 
Fig. 1 Map showing the location of the study sites. HZ Health Zone; HC Health Centre
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combination therapy, AS-AQ or AL. Alternatively, paren-
teral artesunate was given for a maximum of 7 days, until 
oral treatment could be taken reliably.
Patients were followed up at day 7, day 14, day 21 and 
day 28 after discharge. Artesunate was provided free of 
charge by the manufacturer (Guilin Pharmaceuticals, 
Shanghai, PDR China) while the costs of quinine were 
covered by the study. In each study site, patients were 
managed by local clinicians (hospitals) or nurses (health 
centres), while the research team carried out a weekly 
supervision at each study site throughout the dura-
tion of the study. The NMCP provided policy support. 
All authorizations for drug importation were obtained 
from the Ministry of Health through the National 
Drug Authority. All relevant authorities were actively 
involved in the planning of the study and preliminary 
results of the study were shared and discussed during 
stakeholders meetings. Unpublished preliminary results 
of the study were used by the NMCP to develop train-
ing manuals for healthcare providers and communica-
tion tools in prevision of the deployment of injectable 
artesunate.
Data collection
Two questionnaires were used to collect data. Interviews 
were conducted by nine trained interviewers recruited 
from the local community. Two of them were physicians, 
four were nurses and three were social workers. The two 
physicians were recruited from Kinshasa and conducted 
interviews with all study physicians. Two nurses and one 
social worker were recruited in Kinshasa and conducted 
interviews respectively with nurses and patients/caretak-
ers in Kinshasa sites. Two nurses and two social workers 
were recruited in Bas Congo and conducted interviews 
respectively with nurses and patients/caretakers in 
Bas Congo sites. These interviewers were supervised 
by study field scientists. A three-day training was given 
to all interviewers prior to data collection. The training 
included familiarization with the study tools and practic-
ing interviews. Basic techniques of probing and recording 
responses were also discussed during the training. Inter-
view guides were developed and pre-tested prior to use.
Interviews with care providers focused on ease of appli-
cation and drug handling, perceived safety of the treat-
ment, quality of the patient management, perception of 
Fig. 2 Injectable artesunate job aid (poster)
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old versus new treatment on staff work load, and level of 
satisfaction with the new treatment. The core questions 
of the interviews compared injectable artesunate and 
quinine. While obviously there could have been a recall 
bias due to the fact that the interviews were done during 
the artesunate phase of the study, about 3–6 months after 
the quinine phase, this should not have been too much 
of an issue since quinine has been used for decades in 
the DRC, and all health care providers were very familiar 
with its use.
Interviews with patients/caretakers took place dur-
ing the follow up visits and focused on the perception 
of the effectiveness and safety of injectable artesunate, 
especially with regard to adverse events. Here, recall bias 
could have been more of an issue since patients were less 
familiar with quinine adverse events. In order to mini-
mize this problem, one inclusion criterion for the inter-
views of patients/caretakers was a past experience with 
quinine treatment, either for themselves or for one mem-
ber of the family.
According to the interviewee’s preference, interviews 
were conducted in French, the official language in DR 
Congo or in Lingala and Kikongo, the languages spoken 
in Kinshasa and Bas–Congo, respectively. Interviews 
typically lasted between 20 and 30 min. Multiple choice 
closed-ended questions were followed by open-ended 
questions to collect narrative responses. All answers were 
recorded in French by the interviewers.
Ethics
The MATIAS study protocol was reviewed and approved 
by the ethics committee of the Kinshasa School of Public 
Health (University of Kinshasa) and by the ethics com-
mission of both cantons of Basel, EKBB (Ethikkommission 
beider Basel) in Switzerland. Informed verbal consent 
was obtained from health care providers, patients and 
caretakers who participated in the study.
Data processing and analysis
Quantitative data were entered electronically using Epi 
data 3.1 (Epidata Association; Odense, Denmark). After 
standard quality control checks, data were transferred 
to Stata version 12 (Stata Corporation; College Station, 
Texas) for analysis. Categorical variables were compared 
using pearson’s Chi square test or fisher’s exact test in 
case the expected value of any of the cells of the table 
was less than five. A p value ≤0.05 was considered sta-
tistically significant. Qualitative data were summarized 
in emerging themes which were coded and entered 
using Epi data 3.1. They are presented as proportions 
of different variables. Some answers are reported as 
narratives.
Results
Health care providers
Key results of interviews with health care providers are 
summarized in Table  1. A total of 31 health care pro-
viders were interviewed, whereby medical doctors and 
nurses accounted for 22.6  % (7/31) and 77.4  % (24/31) 
of the interviewed personnel, respectively. The median 
number of providers interviewed per health facility was 
four, ranging from three to five per facility. The majority 
of the personnel interviewed (28/31, 90.3  %) had more 
than 3 years of working experience, whilst three individu-
als (9.7 %) had 1–3 years experience. None of the health 
care providers interviewed had used injectable artesunate 
before the beginning of the study.
Ease of use
Questions related to the handling of the drug were only 
asked to the 24 nurses who were responsible for the 
drug preparation and administration. Compared to qui-
nine, eighteen (75 %) of all interviewed nurses reported 
to have spent less time to prepare and administer inject-
able artesunate, 3 (12.5 %) spent more time and 3 (12.5 %) 
said to have spent the same amount of time (Table  1). 
Eighteen (75  %) found it less difficult to prepare inject-
able artesunate compared to quinine, 3 (12.5 %) found it 
more difficult and three reported to have experienced the 
same level of difficulty (Table 1). All those who found it 
more difficult to prepare injectable artesunate compared 
to quinine specified that too many steps were needed in 
artesunate preparation. For patients above 50  kg body 
weight, a minimum of three vials are needed for a single 
dose and obviously this increased the time spent in drug 
preparation since each vial must be opened and reconsti-
tuted separately.
All interviewed nurses involved in the administra-
tion of the treatment found it less difficult to administer 
artesunate compared to quinine. The most important 
reasons cited by the respondents were the rapid means 
of administration (62.5 %), no accidents related to infu-
sion (45.8  %) and the reduced patient monitoring time 
(20.8  %) (Table  1). None of the nurses interviewed 
encountered problems during drug preparation and drug 
administration.
Perceived effectiveness and safety
Regarding the time to observe clinical effects, twenty 
nine (93.6  %) health workers reported that it took less 
time compared to quinine, 1 (3.2 %) estimated it took the 
same time and one (3.2 %) estimated it took more time 
(Table 1). 30 (96.7 %) health care providers reported to be 
very satisfied with the capacity of injectable artesunate to 
cure the symptoms of their patients compared to quinine, 
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1 (3.2  %) experienced the same satisfaction level, and 
none found injectable artesunate less satisfactory.
Seven (22.6 %) health workers reported to have noticed 
adverse drug reactions: The most common ones men-
tioned were a decrease of haemoglobin rate (71.4  %), 
shivering following the drug injection (42.9  %) and loss 
of weight (14.3  %). However, all the seven health care 
providers who reported adverse drug reactions answered 
that they were less frequent than those observed with 
quinine (Table 1).
Table 1 Summary of interviews with health care providers
Question/parameter Frequency Percentage [95 % CI]
Did you spend more or less time to prepare artesunate compared to quinine (N = 24)?
 More time 3 12.5 [2.7, 32.4]
 Same time 3 12.5 [2.7, 32.4]
 Less time 18 75 [53.3, 90.2]
Did you find more or less difficult to prepare artesunate compared to quinine (N = 24)?
 More difficult 3 12.5 [2.7, 32.4]
 Same difficulty 3 12.5 [2.7, 32.4]
 Less difficult 18 75 [53.3, 90.2]
Most cited reasons to support ease of use of injectable artesunate (N = 24)
 Rapid way of administration 15 62.5 [40.6, 81.2]
 No accidents related to infusion 11 45.8 [25.6, 67.2]
 Reduced patient’s monitoring time 5 20.8 [7.1, 42.2]
Time to observe effects of injectable artesunate compared to quinine (N = 31)?
 Less time 29 93.6 [78.6, 99.2]
 Same time 1 3.2 [0.1, 16.7]
 More time 1 3.2 [0.1, 16.7]
Have you noticed any adverse events that you think could be related to artesunate (N = 31)?
 Yes 7 22.6 [9.6, 41.1]
 No 24 77.4 [58.9, 90.4]
Which adverse events did you notice (N = 7)
 Decrease of haemoglobin level 5 71.4 [29.0, 96.3]
 Shivering after drug injection 3 42.9 [9.9, 81.6]
 Loss of weight 1 14.3 [0.4, 57.9]
If you noticed adverse events, would you say that: (N = 7)
 They are less than those observed with quinine 7 100
 They are the same than those observed with quinine 0 0
 They are more than those observed with quinine 0 0
 Don’t know 0 0
Do you think that the workload has reduced with artesunate compare to quinine (N = 31)?
 The workload has diminished 26 83.9 [66.3, 95.4]
 The workload is the same 4 12.9 [3.6, 29.8]
 The workload has increased 1 3.2 [0.1, 16.7]
What is your level of satisfaction with injectable artesunate (N = 31)?
 Very satisfied 19 61.3 [42.2, 78.2]
 Satisfied 12 38.7 [21.8, 57.8]
 Dissatisfied 0 0
Most important reasons for being very satisfied/satisfied with injectable artesunate N = 31)
 Lack of adverse events 17 54.8 [36.0, 72.7]
 Rapid action of the drug 15 48.3 [30.2, 66.9]
 Easy way to prepare and administer 9 29.0 [12.4, 48.0]
 Injectable artesunate more effective 9 29.0 [12.4, 48.0]
 Work load reduction 8 25.8 [11.9, 44.6]
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Patient management
The majority (96.8  %) of health care providers reported 
to have dedicated less time for patient monitoring after 
administration of artesunate compared to quinine. This 
proportion was not significantly different according to 
the type of health facility (hospitals versus health cen-
tres; p  =  0.388 Fisher’s exact test). Of all health care 
providers interviewed, 26 (83.9  %) reported that the 
personnel workload had diminished with the use of 
injectable artesunate, 4 (12.9  %) reported the workload 
to be the same, while 1 (3.2  %) reported that the work-
load had increased (Table  1). The most important rea-
sons for reported workload reductions were reduced 
patient monitoring time (88.5  %), saving of time by 
health personnel (80.7 %) and shorter treatment duration 
(15.4 %). A reason reported by one health care provider 
from Ngeba Health Centre for workload increase was 
increased patient monitoring time.
Care providers general satisfaction
When health care providers were asked about their level 
of satisfaction with injectable artesunate they were either 
satisfied (38.7 %, 12/31) or very satisfied (61.3 %, 19/31) 
with the new treatment, with nobody giving negative 
feedback (Table  1). Reasons for being satisfied/very sat-
isfied were lack of adverse events (54.8  %), rapid action 
of the drug (48.4  %), the easy way the drug is prepared 
and administered (29  %), injectable artesunate being 
more effective (29  %) compared to quinine and work-
load reduction (25.8 %). The level of satisfaction towards 
injectable artesunate was not significantly different 
among type of health facility (hospitals versus health cen-
tres; p =  0.452 Fisher’s exact test) and health care pro-
viders (medical doctors versus nurses; p = 0.384 Fisher’s 
exact test).
A nurse said about injectable artesunate: “ …I am very 
satisfied, it makes work easier, we have good time manage-
ment, patient monitoring has been improved, there are no 
side effects, it has reduced mortality rate among children 
treated, the drug has attracted many patients to come to 
our health facility”.
A medical doctor stated: “very satisfied… it responds 
well, no side effects, but there’s a risk of a high cost because 
it is so precise and easier to use that such a product can 
only be more expensive than quinine… Good outcome 
after treatment.”
Patients or caretakers
Results of interviews with patients/caretakers are sum-
marized in Table  2. A total of 134 patients/caretakers 
were interviewed (124 caretakers and 10 patients aged 
12  years or older). There were more female (73.3  %, 
96/134) than male (26.7  %, 35/134) respondents (p 
value  <0.05). Of the 124 caretakers interviewed, 76 
(61.3  %) were mothers of patients, 33 (26.6  %) were 
fathers, 14 (11.3  %) were other members of the family 
and the remaining 1 (0.8 %) was another member of the 
neighbourhood who accompanied a two-year old female 
patient at Ceco Health Centre.
Effectiveness and safety
With regards to the time needed for injectable artesu-
nate to cure the symptoms of the patients, the large 
majority of respondents (93.3  %, N  =  125) felt that 
it took less time compared to quinine, while 8 (6  %) 
respondents said it took the same time and 1 (0.7  %) 
more time. 46 (34.6  %) respondents reported to have 
noticed adverse events; asthenia (63  %) and loss of 
appetite (15.2  %) were the most common ones, while 
87 (65.4  %) did not report any complication. The pro-
portion of patients/caretakers reporting adverse events 
was not significantly different from that of care pro-
viders (X2 =  1.593, p value =  0.207). Statistical analy-
sis showed no significant difference in the occurrence 
of adverse events between patients less than and more 
than 5  years of age (X2 =  0.162, p value =  0.687). Of 
those who reported to have noticed adverse events, 
32 (69.6  %) considered that they were less than those 
observed with quinine, while 7 (15.2  %) and 1 (2.1  %) 
said respectively they are the same and more than those 
observed with quinine. 6 (13.1  %) did not know. The 
point made above on recall bias calls for some caution 
in the interpretation of these results.
Satisfaction
Regarding general satisfaction towards the ability of 
injectable artesunate to cure the symptoms that moti-
vated the patients’ consultation, the vast majority of 
patients/caretakers (95.5  %, N  =  128) reported to have 
been either satisfied or very satisfied (Table 2). Six (4.5 %) 
reported being less satisfied than with quinine, of whom 
three reported persistent fever as a main reason for their 
dissatisfaction, while 2 (33.3  %) reported asthenia and 
dizziness. One respondent said he did not know what 
could be the long-term side effects of this new drug. 
Patients/caretakers level of satisfaction was not signifi-
cantly different among type of health facility they con-
sulted (p value =  0.46, Fisher’s exact test) and patient’s 
age (p value  =  0.77 Fisher’s exact test). When asked if 
they would choose or recommend injectable artesunate 
over quinine again next time for themselves or a family 
member, the majority of respondents (97.7  %) said they 
would choose injectable artesunate. The most important 
reasons for choosing artesunate were rapid action (47 %), 
no or less adverse events (44.5  %), shorter treatment 
course and a shorter hospital stay (26.5 %) (Table 2).
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A mother said: “This is a short duration treatment, the 
symptoms disappear quickly. There is less manipulation 
compared to quinine, where you have to be in bed for 4 
hours of infusion but with this treatment, just a few min-
utes of injection. This drug takes less time compared to 
quinine and there are no side effects. I think it is better 
suited to malaria treatment for children”.
A young mother said: “Very satisfied - After the first 
injection, my child was doing fine already. The fever had 
dropped quickly. The treatment duration is very short. We 
stayed for a short time at the hospital”.
Discussion
This study was designed to assess the feasibility and 
acceptability of the implementation of IV/IM artesu-
nate from the perspective of care providers, as well as 
its acceptability (versus quinine treatment) from the 
perspective of the patients/caretakers. Results clearly 
show that use of injectable artesunate for the treatment 
of severe malaria in the context of the DRC is both fea-
sible and well accepted. Patients/caretakers were very 
receptive to the new drug as they perceived it as being 
highly effective. Despite a few number of health providers 
reporting that several steps were needed in the prepara-
tion of artesunate, the handling of the drug was perceived 
to be easy. The vast majority of providers reported to 
have spent less time in this task. This is consistent with 
the results of quantitative measures of time and motion 
reported by Ferrari et al., which showed that the overall 
cumulative staff time dedicated to drug pre-administra-
tion tasks was 20  min for quinine compared to 13  min 
for artesunate. This difference is expected to improve in 
favour of the latter with health personnel gaining more 
experience [16].
Drug formulation had a significant impact on the dura-
tion of the preparation and administration. The drug 
used in the study was packaged in vials of 60 mg which, 
when reconstituted, was equivalent to 6 ml of solution for 
the intravenous route. For an average 60 kg body weight 
adult, this equates to prepare three vials and repeating 
three times all steps of preparation, resulting in a longer 
preparation time.
Table 2 Summary of interviews with patients/caretakers
Question/parameter Frequency Percentage [95 % CI]
Time to observe effects of injectable artesunate compared to quinine (N = 134)?
 Less time 125 93.3 [87.6, 96.9]
 Same time 8 6 [2.6, 11.4]
 More time 1 0.7 [0.0, 4.1]
Have you noticed any adverse event that you think could be related to artesunate (N = 134)?
 Yes 46 34.3 [26.4, 43.0]
 No 88 65.7 [57.0, 73.7]
If you noticed adverse events, would you say that: (N = 46)
 They are less than those observed with quinine 32 69.6 [54.3, 82.3]
 They are the same than those observed with quinine 7 15.2 [6.3, 28.9]
 They are more than those observed with quinine 1 2.1 [0.0, 11.5]
 Don’t know 6 13.1 [4.9, 26.3]
If you had to make the choice in the future between quinine and artesunate, which one would you choose (N = 121)?
 Quinine 4 3.3 [0.9, 8.2]
 Artesunate 117 96.7 [91.8, 99.1]
What is your level of satisfaction towards injectable artesunate (N = 134)?
 Dissatisfied 6 4.5 [1.7, 9.5]
 Satisfied 66 49.2 [40.5, 58.0]
 Very satisfied 62 46.3 [37.6, 55.1]
Most important reasons for choosing injectable artesunate instead of injectable quinine (N = 117)
 Rapid action 55 47.0 [37.7, 56.5]
 No side effects 38 32.5 [24.1, 41.8]
 Short treatment course 24 20.5 [13.6, 28.9]
 Less side effects 14 12.0 [6.7, 19.3]
 Rapid way of administration 13 11.1 [6.1, 18.3]
 Short hospital stay 7 6.0 [2.4, 11.9]
 More effective 5 4.2 [1.4, 9.7]
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On the other hand, this drug formulation may cause 
significant drug wastage especially in small children 
who need small quantities. As the reconstituted solu-
tion is only stable for 1 hour, and since an opened vial 
cannot be reused, it is possible to lose up to more than 
half of the vial. In the context of limited resources, it 
is important that drug manufacturers develop adapted 
and easy-to-use forms of injectable artesunate.
Contrary to artesunate, the administration of qui-
nine requires special precautions because of its poten-
tial toxicity, and close monitoring of the patient as the 
risk of incorrect dosage and severe side effects is high 
[9, 19–21]. This leads to a reduced patient monitoring 
time with the use of injectable artesunate which may 
explain the reported reduction of personnel workload 
which in turn has the potential to improve the quality 
of care.
The superior efficacy of injectable artesunate com-
pared to intravenous quinine in the management of 
severe malaria has been demonstrated in clinical trials 
[6–8]. Because of its small-scale nature based on pur-
posive sampling, this study cannot draw a conclusion on 
the effectiveness of injectable artesunate. However, both 
health care providers and patients/caretakers perceive 
artesunate to be highly effective.
The findings from this study are consistent with what is 
known so far about the better short-term safety of artesu-
nate compared to quinine [6] [22]. Patients/caretakers 
did not report significant adverse event, the commonly 
reported adverse events (asthenia and loss of appetite) 
may be disease induced.
The most common adverse events reported by health 
workers was a decrease in haemoglobin, a fact support-
ing recent findings on the occurrence of delayed anaemia 
after parenteral artesunate for severe malaria [13–15]. 
However, the training received by health workers before 
the implementation of artesunate had an emphasis on 
the monitoring of adverse events and especially a drop in 
haemoglobin, and this may have influenced the frequency 
of reporting. The results of this study cannot be used to 
draw conclusion on the safety of intravenous artesunate, 
but rather only as supportive evidence to the acceptabil-
ity of the new treatment.
The design without concurrent controls, the relatively 
small scale of the study and the purposive sampling con-
stitute a limitation to the generalizability of the findings. 
The majority of interview questions were comparative 
between quinine and artesunate and the time between 
interviews and prior experience with quinine treatment 
was not recorded, this might have led to a recall bias, 
especially for interviews with patients/caretakers. Cour-
tesy bias in respondents’ answers might be possible as 
the drug cost was free for patients and interviewed health 
care providers were involved in the MATIAS project. 
In order to minimize this, interviews were conducted 
by independent interviewers recruited from the local 
community.
One of the major challenges in switching from qui-
nine to injectable artesunate may be the reluctance of 
health care workers to switch to a new treatment [23]. In 
this study, the majority of health care providers were not 
aware of the latest evidence on safety and efficacy, and 
they are very familiar with quinine treatment. Hence, it is 
important to promote the benefits of injectable artesunate 
among health workers and train them well in the use of 
the new treatment. The new treatment guidelines should 
be included as soon as possible in the training curricula in 
medical and nursing schools, and public awareness of the 
new drug should be raised through effective communica-
tion channels.
Conclusions
The findings from this study showed that the use of 
injectable artesunate for the management of severe 
malaria in hospitals and health centres of the DRC is 
feasible and acceptable to both care providers and 
patients/caretakers. The handling of the drug was per-
ceived to be easy. Injectable artesunate was perceived 
to be very effective and safe. Training of health person-
nel is a key factor for a successful implementation. This 
study provides for the first time operational evidence 
to support the roll out of injectable artesunate in the 
DRC.
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